Gambogic acid suppresses pancreatic fibrosis via inhibiting YAP1-mediated activation of pancreatic stellate cells

Abstract

The activation of pancreatic stellate cells (PSCs) and the secretion of inflammatory factors play critical roles in the development of pancreatic fibrosis. While gambogic acid (GA), a flavonoid with anti-tumor properties, has been studied, its role in this process remains unclear. This study demonstrated that GA promoted YAP1 degradation and reduced its nuclear localization, thereby inhibiting PSC activation and the progression of pancreatic fibrosis. GA inhibited PSC proliferation, decreased α-smooth muscle actin (α-SMA) expression, and reduced lipid droplets in LTC14 and primary mouse PSCs (mPSCs). Additionally, GA suppressed the expression of inflammatory factors [nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3), nuclear factor erythroid 2-related factor 2 (NRF2), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and nuclear factor κB (NF-κB)] in PSCs and counteracted the transforming growth factor (TGF)-β-induced increase in these proteins. GA also reduced collagen Ι and tissue inhibitor of metalloproteinase-1 (TΙMP1) expression, thereby attenuating fibrosis. Mechanistically, GA decreased YAP1 expression and nuclear translocation and reversed TGF-β-induced YAP1 upregulation. YAP1 overexpression abrogated GA’s inhibitory effects on PSC activation and inflammation. Furthermore, GA activated the Hippo pathway, increased phosphorylated (p)-LATS1 and p-YAP levels, and promoted ubiquitin-mediated YAP1 degradation. In vivo studies confirmed that GA inhibited dibutyltin dichloride (DBTC)-induced pancreatic fibrosis via suppressing YAP1 and NF-κB in BALB/c mice. In conclusion, GA activates the Hippo pathway and promotes YAP1 translocation to the cytoplasm, leading to its degradation and subsequent inhibition of PSC activation and fibrosis. These findings highlight the critical role of ubiquitin-mediated YAP1 degradation in regulating PSC activity and offer novel insights into the therapeutic potential of GA for treating pancreatic fibrosis.

Keywords

Pancreatic fibrosis / Pancreatic stellate cells / Gambogic acid / YAP1

References

[1] Beyer G, Habtezion A, Werner J, et al. Chronic pancreatitis. Lancet. 2020; 396(10249):499-512. https://doi.org/10.1016/S0140-6736(20)31318-0.

[2] Vege SS, Chari ST. Chronic pancreatitis. N Engl J Med. 2022; 386(9):869-878. https://doi.org/10.1056/NEJMcp1809396.

[3] Dib B. A study of intrathecal self-injection of morphine by rats, and the difficulties entailed. Pain. 1985; 23(2):177-185. https://doi.org/10.1016/0304-3959(85)90058-2.

[4] Zhang W, Zhang S, Zhang W, et al. Matrix stiffness and its influence on pancreatic diseases. Biochim Biophys Acta Rev Cancer. 2021; 1876(1): 188583. https://doi.org/10.1016/j.bbcan.2021.188583.

[5] An J, Jiang T, Qi L, et al. Acinar cells and the development of pancreatic fibrosis. Cytokine Growth Factor Rev. 2023;71-72:40-53. https://doi.org/10.1016/j.cytogfr.2023.05.003.

[6] Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019; 18(1):14. https://doi.org/10.1186/s12943-018-0927-5.

[7] Baer JM, Zuo C, Kang L, et al. Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC. Nat Immunol. 2023; 24(9):1443-1457. https://doi.org/10.1038/s41590-023-01579-x.

[8] Schnittert J, Bansal R, Prakash J. Targeting pancreatic stellate cells in cancer. Trends Cancer. 2019; 5(2):128-142. https://doi.org/10.1016/j.trecan.2019.01.001.

[9] Wang Y, Chen K, Liu G, et al. Disruption of super-enhancers in activated pancreatic stellate cells facilitates chemotherapy and immunotherapy in pancreatic cancer. Adv Sci (Weinh). 2024; 11(16):e2308637. https://doi.org/10.1002/advs.202308637.

[10] Wang D, Han S, Lv G, et al. Pancreatic acinar cells-derived sphingosine-1-phosphate contributes to fibrosis of chronic pancreatitis via inducing autophagy and activation of pancreatic stellate cells. Gastroenterology. 2023; 165(6):1488-1504.e20. https://doi.org/10.1053/j.gastro.2023.08.029.

[11] Sarkar R, Xu Z, Perera CJ, et al. Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer. Semin Cancer Biol. 2023; 93:114-122. https://doi.org/10.1016/j.semcancer.2023.05.007.

[12] Yang X, Chen J, Wang J, et al. Very-low-density lipoprotein receptor-enhanced lipid metabolism in pancreatic stellate cells promotes pancreatic fibrosis. Immunity. 2022; 55(7):1185-1199.e8. https://doi.org/10.1016/j.immuni.2022.06.001.

[13] Wu Y, Zhang C, Guo M, et al. Targeting pancreatic stellate cells in chronic pancreatitis: focus on therapeutic drugs and natural compounds. Front Pharmacol. 2022;13:1042651. https://doi.org/10.3389/fphar.2022.1042651.

[14] Huang C, Iovanna J, Santofimia-Castaño P. Targeting fibrosis: the bridge that connects pancreatitis and pancreatic cancer. Int J Mol Sci. 2021; 22(9):4970. https://doi.org/10.3390/ijms22094970.

[15] Sherman MH. Stellate cells in tissue repair, inflammation, and cancer. Annu Rev Cell Dev Biol. 2018; 34:333-355. https://doi.org/10.1146/annurev-cellbio-100617-062855.

[16] Ramakrishnan P, Loh WM, Gopinath SCB, et al. Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer. Acta Pharm Sin B. 2020; 10(3):399-413. https://doi.org/10.1016/j.apsb.2019.11.008.

[17] Li W, Sun L, Lei J, et al. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor-stromal crosstalk under hypoxic conditions via the IL-6/ERK/NF-κB axis. Oncol Rep. 2020; 44(1):382-392. https://doi.org/10.3892/or.2020.7600.

[18] Zeng XP, Zeng JH, Lin X, et al. Puerarin ameliorates caerulein-induced chronic pancreatitis via inhibition of MAPK signaling pathway. Front Pharmacol. 2021;12:686992. https://doi.org/10.3389/fphar.2021.686992.

[19] Garg B, Giri B, Modi S, et al. NFκB in pancreatic stellate cells reduces infiltration of tumors by cytotoxic T cells and killing of cancer cells, via up-regulation of CXCL12. Gastroenterology. 2018; 155(3):880-891.e8. https://doi.org/10.1053/j.gastro.2018.05.051.

[20] Zhao T, Xiao D, Jin F, et al. ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour-stromal IL-1β/NF-κB/ESE3 signalling axis. Br J Cancer. 2022; 127(8):1461-1472. https://doi.org/10.1038/s41416-022-01927-y.

[21] Wu N, Xu XF, Xin JQ, et al. The effects of nuclear factor-kappa B in pancreatic stellate cells on inflammation and fibrosis of chronic pancreatitis. J Cell Mol Med. 2021; 25(4):2213-2227. https://doi.org/10.1111/jcmm.16213.

[22] Morvaridi S, Dhall D, Greene MI, et al. Role of YAP and TAZ in pancreatic ductal adenocarcinoma and in stellate cells associated with cancer and chronic pancreatitis. Sci Rep. 2015;5:16759. https://doi.org/10.1038/srep16759.

[23] Wu Y, Aegerter P, Nipper M, et al. Hippo signaling pathway in pancreas development. Front Cell Dev Biol. 2021;9:663906. https://doi.org/10.3389/fcell.2021.663906.

[24] Tanaka HY, Nakazawa T, Miyazaki T, et al. Targeting ROCK2 improves macromolecular permeability in a 3D fibrotic pancreatic cancer microenvironment model. J Control Release. 2024; 369:283-295. https://doi.org/10.1016/j.jconrel.2024.03.041.

[25] Cortes E, Sarper M, Robinson B, et al. GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment. EMBO Rep. 2019; 20(1):e46556. https://doi.org/10.15252/embr.201846556.

[26] Xiao Y, Zhang H, Ma Q, et al. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Cancer Lett. 2019; 462:51-60. https://doi.org/10.1016/j.canlet.2019.07.015.

[27] Yuan Y, Li Z, Li M, et al. Mitochondria oxidative stress mediated nicotine-promoted activation of pancreatic stellate cells by regulating mitochondrial dynamics. Toxicol In Vitro. 2022;84:105436. https://doi.org/10.1016/j.tiv.2022.105436.

[28] Xue R, Wang J, Yang L, et al. Coenzyme Q 10 ameliorates pancreatic fibrosis via the ROS-triggered mTOR signaling pathway. Oxid Med Cell Longev. 2019;2019:8039694. https://doi.org/10.1155/2019/8039694.

[29] Ryu GR, Lee E, Chun HJ, et al. Oxidative stress plays a role in high glucose-induced activation of pancreatic stellate cells. Biochem Biophys Res Commun. 2013; 439(2):258-263. https://doi.org/10.1016/j.bbrc.2013.08.046.

[30] Dey A, Varelas X, Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov. 2020; 19(7):480-494. https://doi.org/10.1038/s41573-020-0070-z.

[31] Ryan MB, Der CJ, Wang-Gillam A, et al. Targeting RAS-mutant cancers: is ERK the key? Trends Cancer. 2015; 1(3):183-198. https://doi.org/10.1016/j.trecan.2015.10.001.

[32] O'Neil BH, Scott AJ, Ma WW, et al. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015; 26(9):1923-1929. https://doi.org/10.1093/annonc/mdv264.

[33] Yu Z, Jv Y, Cai L, et al.Gambogic acid attenuates liver fibrosis by inhibiting the PI3K/AKT and MAPK signaling pathways via inhibiting HSP90. Toxicol Appl Pharmacol. 2019; 371:63-73. https://doi.org/10.1016/j.taap.2019.03.028.

[34] Wang L, Li S, Yao Y, et al. The role of natural products in the prevention and treatment of pulmonary fibrosis: a review. Food Funct. 2021; 12(3):990-1007. https://doi.org/10.1039/D0FO03001E.

[35] Xu Y, Zhang X, Zhang R, et al. AFP deletion leads to anti-tumorigenic but pro-metastatic roles in liver cancers with concomitant CTNNB1 mutations. Cancer Lett. 2023;566:216240. https://doi.org/10.1016/j.canlet.2023.216240.

[36] Kumar K, DeCant BT, Grippo PJ, et al. BET inhibitors block pancreatic stellate cell collagen I production and attenuate fibrosis in vivo. JCI Insight. 2017; 2(3):e88032. https://doi.org/10.1172/jci.insight.88032.

[37] Bhattacharjee S, Hamberger F, Ravichandra A, et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021; 131(11):e146987. https://doi.org/10.1172/JCI146987.

[38] Kapoor A, Yao W, Ying H, et al. Yap1 activation enables bypass of oncogenic kras addiction in pancreatic cancer. Cell. 2019; 179(5):1239. https://doi.org/10.1016/j.cell.2019.10.037.

[39] Liu M, Zhang Y, Yang J, et al. Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer. Gastroenterology. 2021; 160(5):1771-1783.e1. https://doi.org/10.1053/j.gastro.2020.12.077.

[40] Mooring M, Fowl BH, Lum SZC, et al. Hepatocyte stress increases expression of yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis. Hepatology. 2020; 71(5):1813-1830. https://doi.org/10.1002/hep.30928.

[41] Hong AW, Meng Z, Yuan HX, et al. Osmotic stress-induced phosphorylation by NLK at Ser128 activates YAP. EMBO Rep. 2017; 18(1):72-86. https://doi.org/10.15252/embr.201642681.

[42] Ni W, Yao S, Zhou Y, et al. Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m(6)A reader YTHDF3 Mol Cancer. 2019; 18(1):143. https://doi.org/10.1186/s12943-019-1079-y.

[43] Pothula SP, Xu Z, Goldstein D, et al. Key role of pancreatic stellate cells in pancreatic cancer. Cancer Lett. 2016; 381(1):194-200. https://doi.org/10.1016/j.canlet.2015.10.035.

[44] Hatami E, Jaggi M, Chauhan SC, et al. Gambogic acid: a shining natural compound to nanomedicine for cancer therapeutics. Biochim Biophys Acta Rev Cancer. 2020; 1874(1): 188381. https://doi.org/10.1016/j.bbcan.2020.188381.

[45] Qu Y, Zhang G, Ji Y, et al. Protective role of gambogic acid in experimental pulmonary fibrosis in vitro and in vivo. Phytomedicine. 2016; 23(4):350-358. https://doi.org/10.1016/j.phymed.2016.01.011.

[46] Tao S, Yang L, Wu C, et al. Gambogenic acid alleviates kidney fibrosis via epigenetic inhibition of EZH2 to regulate Smad7-dependent mechanism. Phytomedicine. 2022;106:154390. https://doi.org/10.1016/j.phymed.2022.154390.

[47] Liu Y, Lu T, Zhang C, et al. Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury. J Hepatol. 2019; 71(4):719-730. https://doi.org/10.1016/j.jhep.2019.05.029.

[48] Franklin JM, Wu Z, Guan KL. Insights into recent findings and clinical application of YAP and TAZ in cancer. Nat Rev Cancer. 2023; 23(8):512-525. https://doi.org/10.1038/s41568-023-00579-1.

[49] Liu J, Bai W, Zhou T, et al. SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation. Gut. 2023; 72(9):1722-1737. https://doi.org/10.1136/gutjnl-2022-327492.

[50] Guo Y, Cui Y, Li Y, et al. Cytoplasmic YAP1-mediated ESCRT-III assembly promotes autophagic cell death and is ubiquitinated by NEDD4L in breast cancer. Cancer Commun (Lond). 2023; 43(5):582-612. https://doi.org/10.1002/cac2.12417.

[51] Ibar C, Irvine KD. Integration of Hippo-YAP signaling with metabolism. Dev Cell. 2020; 54(2):256-267. https://doi.org/10.1016/j.devcel.2020.06.025.

[52] Wang T, Wang D, Sun Y, et al. Regulation of the Hippo/YAP axis by CXCR7 in the tumorigenesis of gastric cancer. J Exp Clin Cancer Res. 2023; 42(1):297. https://doi.org/10.1186/s13046-023-02870-3.

[53] Bordeleau F, Mason BN, Lollis EM, et al. Matrix stiffening promotes a tumor vasculature phenotype. Proc Natl Acad Sci U S A. 2017; 114(3):492-497. https://doi.org/10.1073/pnas.1613855114.

[54] Wu Y, Zhang C, Jiang K, et al. The role of stellate cells in pancreatic ductal adenocarcinoma: targeting perspectives. Front Oncol. 2020;10:621937. https://doi.org/10.3389/fonc.2020.621937.

[55] Yang K, Xu J, Fan M, et al. Lactate suppresses macrophage pro-inflammatory response to LPS stimulation by inhibition of YAP and NF-κB activation via GPR81-mediated signaling. Front Immunol. 2020;11:587913. https://doi.org/10.3389/fimmu.2020.587913.

[56] LaCanna R, Liccardo D, Zhang P, et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J Clin Invest. 2019; 129(5):2107-2122. https://doi.org/10.1172/JCI125014.

[57] Banik K, Harsha C, Bordoloi D, et al. Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. Cancer Lett. 2018; 416:75-86. https://doi.org/10.1016/j.canlet.2017.12.014.

[58] Qi Q, You Q, Gu H, et al. Studies on the toxicity of gambogic acid in rats. J Ethnopharmacol. 2008; 117(3):433-438. https://doi.org/10.1016/j.jep.2008.02.027.

[59] Zhang D, Wang W, Hou T, et al. New delivery route of gambogic acid via skin for topical targeted therapy of cutaneous melanoma and reduction of systemic toxicity. J Pharm Sci. 2021; 110(5):2167-2176. https://doi.org/10.1016/j.xphs.2020.12.024.

[60] Jiang LL, Li K, Lin QH, et al. Gambogic acid causes fin developmental defect in zebrafish embryo partially via retinoic acid signaling. Reprod Toxicol. 2016; 63:161-168. https://doi.org/10.1016/j.reprotox.2016.06.004.